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454 Life Sciences: Illuminating the future
of genome sequencing and personalized
medicine
Kristin L. Patrick
Yale University School of Medicine, New Haven, Connecticut
Imagine going to the doctor with a mi-
graine headache and knowing the next day
whether your DNA is to blame. Or better
yet, imagine knowing whether your DNA
encodes a risk for migraines even before a
headache strikes. If 454 Life Sciences’
dream is realized, doctors will be able to
quickly and inexpensively unlock the mys-
teries of patients’genomes, revealing indi-
cators of disease susceptibility and
shedding light on the potential efficacy of
particular drug regimens. Due to advances
in technology made by companies like 454
Life Sciences in Branford, Connecticut,
personalized genomic medicine is becom-
ing a reality and is sure to revolutionize not
only your doctor’s visits, but also the way
society views human health and disease.
Founded in 2000 with the mission of
making individual human genome sequenc-
ingareality,454LifeScienceshasprovenit-
self a front-runner in the race toward
personalizing medicine. As the story goes,
454’s founder Jonathan Rothberg, PhD, was
faced with a family health emergency. His
newbornsonwasill,andashewaitedtohear
news from doctors, he pondered the idea of
pinpointing his child’s condition by reading
hisgenome—and,thus,hisquesttoprovide
fast, affordable genome sequencing began.
The first gene sequencing technology
was developed by Frederick Sanger in
1977. The innovation behind the Sanger
method involved the use of dideoxynu-
cleotide triphosphates to terminate elonga-
tion of a DNA primer (a short fragment
complementary to a single-stranded DNA
template of interest). Variations of the
Sanger method have contributed to almost
all of our current knowledge of gene and
genome sequences. However, the technique
has certain limitations. In particular, large-
scale projects like the sequencing of full or-
ganism genomes by the Sanger method
involve the rather laborious task of creating
a library of genomic fragments in bacterial
plasmids, which then are sequenced and as-
sembled. Costly reagents and time-con-
suming sample preparation make this
approach unfeasible for use in a clinical set-
ting, where cheap, fast, and accurate se-
quencing is demanded.
The Sanger method was used for the
Human Genome Project and was the gold
standard for decades — until 1998, when
scientist Mostafa Ronaghi at Stanford Uni-
versity [1,2] worked out the chemistry be-
hind the technology of pyrosequencing, the
method eventuallyadapted by 454 Life Sci-
ences. Pyrosequencing refers to a series ofPatrick: 454 Life Sciences 192
enzymatic reactions during which incorpora-
tion of DNA bases is measured by the re-
lease of visible light. Briefly, a DNA
template is incubated with several enzymes,
including DNA polymerase and ATP sul-
furylase. The subsequent incorporation of
one of the four deoxynucleotide triphos-
phates, or dNTPs, complementary to the
DNA template strand, releases pyrophos-
phate, a compound which then is converted
to ATP by ATP sulfurylase and fuels the lu-
ciferase enzyme to release protons.The light
released by the addition of each new nu-
cleotide is detected and recorded, and the
process is repeated to extend the chain of se-
quenced DNA.
The 454 sequencing technology takes
pyrosequencingonestepfurther,allowingfor
bulk sequencing of an entire genome [3].
First, genomic DNA is fragmented and lig-
ated to specific adapter molecules, which are
usedastemplatesforprimersinapolymerase
chainreaction(PCR).ThePCRreaction,car-
riedoutonsyntheticbeadsinanoilemulsion,
takes a single piece of DNAand replicates it
until 10 million copies of a discrete DNA
molecule are bound to each bead. Next, each
bead is deposited into an individual well of a
fiber-optic slide, where it meets a cocktail of
the enzymes required for the pyrophosphate
reaction.These steps take the place of the la-
borioustaskofcloningindividualDNAmol-
ecules and eliminate biases that can be
introduced by cloning a population of frag-
ments (transformed bacteria will preferen-
tiallyreplicatecertainsequencestretchesover
others).Aloaded slide is then fed into the se-
quencinginstrument,whichwashesdeoxynu-
cleotides over the plate, extending the chains
of DNA templates in each well and promot-
ing photon release. A computer records the
releaseoflight,logsthesequenceoftheDNA
in each well, and eventually interprets these
data to align smaller bits of sequence into a
fullgenomesequence.In2005,454LifeSci-
ences released the genome of Mycoplasma
genitalium, the first organism sequenced by
this technology [3].
Currently, a machine called the Genome
Sequencer FLX does the dirty work at 454
Life Sciences. The strength of this instru-
ment is best expressed not by measures of
length, but of depth: While it only reads
short DNA molecules of 200 to 300 bases,
it can read more than 400,000 of these short
sequences in a single run, providing a truly
ultra-high throughput solution to genome se-
quencing. This is equivalent to more than
100 million total bases per 7.5 hour run,
meaning the machine can sequence the 4.5
million base pair genome of a bacterium
such as E. coli in about two days. Not only
is the newest instrument at 454 Life Sci-
ences fast, it is also incredibly accurate —
consensus reads, meaning the alignments of
many identical sequenced molecules, are
more than 99.99 percent correct.
The Genome Sequencer FLX is not
without shortcomings, however. Because the
technology relies on short reads of only a
couple of hundred base pairs, genomes with
highly repetitive regions cannot be assem-
bled accurately. More broadly, the sequenc-
ing of truly novel organisms presents a
challenge. Without a related species’
genome to use as a template, short base
reads may not contain enough information
to accurately piece together a new genome.
In these cases, several additional sequencing
runs may need to be performed in order to
create a great enough number of reads for
the computer software to overlap separate
sequences with high confidence.
When asked to elaborate on 454’s role in
shaping the DNA sequencing industry, Man-
agerofGlobalMarketingBrendonHillspeaks
ofthe“democratizationofsequencing.”Asde-
scribed by Hill, sequencing organisms’ full
genomes used to be considered “big science”
and only could be tackled by special genome
centers.Now,withthetechnologyandservice
provided by companies such as 454 Life Sci-
ences, the privilege of large-scale sequencing
projects has been stripped from these centers
and other elite academic institutions, opening
up a wide range of opportunities for basic re-
searchers. While, according to Hill, the even-
tual goal of 454 Life Sciences is to bring
genomesequencingtechnologyintothepublic
healthsector,inthemeantimethereisa“lotof
greatsciencetohappenasprogressivelyfaster,
better versions of our instrument come out.”Patrick: 454 Life Sciences 193
Indeed, many researchers have begun
taking advantage of 454’s service, and the
list of peer-reviewed publications made pos-
sible by 454’s technology continues to grow.
To date, 454 has been involved in the de
novo sequencing of bacterial, fungal, and
viral genomes, the sequencing of small RNA
populations, and the elucidation of genomes
from ancient organisms such as the wooly
mammoth and Neanderthal man.
New ways of thinking about pressing
biological questions and even entire new
fields of biology are springing up in light of
the availability of fast, cheap sequencing
technology. One such novel discipline is
metagenomics, or the study of genetic ma-
terial collected en masse from an environ-
mental source. Because machines like the
Genome Sequencer FLX can sequence hun-
dreds of thousands of bases per run, this
depth of coverage allows the sequencing of
a complex slew of genomes without intro-
ducing base changes or biases. 454’s tech-
nology so far has enabled the sequencing of
organisms from places as diverse as hot ther-
mal vents in the depths of theAtlantic Ocean
[4] and soil samples collected from across
the planet [5]. In a rather unique application,
454 sequencing technology was able to pin-
point the probable cause for the collapse in
United States honeybee populations [6]. By
comparing the genomes of microflora found
in hives experiencing colony collapse disor-
der to those collected from normal hives, re-
searchers discovered a virus, the presence of
which strongly correlated to the suffering
hives, presenting a possible explanation for
the loss of worker bees from those colonies.
Not surprisingly, 454 Life Sciences is
not the only company working to increase
the speed and decrease the cost of genome
sequencing. Currently, 454 Life Sciences is
competing for the Archon X Prize in Ge-
nomics alongside Reveo Inc., VisiGen
Biotechnologies, base4 Innovation, Personal
Genome X-team, and the Foundation for
Applied Molecular Evolution. Subsidized by
private investors, the X Prize will be
awarded to the first team to sequence 100
full human genomes in 10 days at a cost of
less than $10,000 per genome. Seeing that it
took two months and just under $1 million
to sequence DNA double-helix decoder Dr.
JamesWatson’s genome, theArchon contest
appears quite a daunting challenge. How-
ever, technologies at 454 continue to im-
prove rapidly: In 2005, 454’s machines
could sequence about 20 million bases per
run. This number increased to about 100
million bases per run in 2007, and, accord-
ing to Hill, the next version of the 454
Genome Sequencer will be able to sequence
approximately a billion bases in a day. With
advances like these, the X Prize may be well
within reach of any of its competitors.
For a time, it appeared genomics would
be dethroned by even more complex ways
of analyzing whole organisms such as tran-
scriptomics or proteomics, whose technolo-
gies look downstream of DNAsequences at
actual messenger RNAs or proteins in a
given cell. When asked to comment on his
company’s “rivals” for scientific knowledge,
Hill at 454 remained undaunted, stating that
“DNA sequencing is a fairly universal tool,
not a proxy for anything else … DNAinfor-
mation is the most basic you want to have.”
Beyond simply creating faster, more af-
fordable technologies, 454 continues to push
thelimitsofgenomesequencing.Researchers
there are working to develop new methods
forhighlyparallelDNAsequencingusingmi-
croarray chips, which are collections of mi-
croscopic spots, each corresponding to a
singlehumangene.Theirso-called“sequence
capture” technology enables researchers to
enrichportionsofthehumangenomeviahy-
bridization to a chip [7]. Such enrichment
eliminates the need for PCR-based amplifi-
cation strategies and will allow for the selec-
tive analysis of specific portions of complex
genomes. For example, one could use se-
quence capture to look exclusively at human
exons,ortheexpressedportionsofthehuman
genome. Alternatively, the technology could
pull out specific regions of the genome en-
coding genes relating to heart disease or can-
cer, thereby facilitating the diagnosis of at
risk-patients, while at the same time adding
to our knowledge of specific mutations or
polymorphisms that lend themselves to the
development of these complex diseases.Patrick: 454 Life Sciences 194
Truly, the future for 454 Life Sciences
and their applications of pyrosequencing
technology is bright.And so may be the fu-
ture of health care and medicine — with im-
provements in genome sequencing, we can
look forward to significant advances in un-
derstanding human disease, developing ef-
fective treatments, and leading longer and
healthier lives.
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